Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 9 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
The Industry Foundation of Chonnam National University shows a broad prosecution profile with 10 pending office actions. These actions are situated within the Biotechnology & Pharmaceuticals technology area. The portfolio involves 10 distinct examiners, which indicates that every pending action is being handled by a different individual. This high level of examiner diversity suggests that the foundation's patent strategy is not reliant on the tendencies of any single reviewer.
Prosecution is spread across 9 distinct art units, reflecting a wide range of specialized subject matter within the biotechnology sector. The busiest examiner, FRASER, STEWART A, is currently managing 1 pending office action. This distribution confirms that no single examiner holds a disproportionate share of the foundation's 10 pending actions. The high number of distinct art units and examiners points to a diverse and fragmented prosecution landscape. For practitioners, this means that insights gained from 1 application may have limited applicability to others in the portfolio, given the variety of 9 distinct art units involved.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (10%) |
| §103 only | 1 (10%) |
| §102 only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 6 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRASER, STEWART A | 1 | 85.9% | +14.5% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
| WELLES, COLMAN THOMAS | 1 | 29.2% | +64.2% |
| RAYMONDA, MATTHEW HAROLD | 1 | 35.7% | +55.0% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
| CONSTANTINE, CHARLES Z | 1 | 58.9% | +49.2% |
| LEE, JAE W | 1 | 65.8% | +38.6% |
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17912480 | ISCHEMIC HEART DISEASE ANIMAL MODEL USING 3-DIMENSIONAL BIOPRINTED OCCLUDE, AND MANUFACTURING METHOD THEREFOR | WESTON, ALYSSA G | 9d |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | WELLES, COLMAN THOMAS | 21d |
| 18065810 | NOVEL MICROORGANISM FOR POLYSTYRENE BIODEGRADATION | LEE, JAE W | 22d |
| 18395922 | NOVEL ORGANOTIN SILICATE COMPOUNDS, PREPARATION METHODS THEREOF AND PHOTORESIST COMPOSITION CONTAINING THE SAME | FRASER, STEWART A | — |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | SCHUBERG, LAURA J | — |
| 18251176 | CONSTRUCT FOR EXPRESSING MONOMERIC STREPTAVIDIN | RAYMONDA, MATTHEW HAROLD | — |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | DUFFY, PATRICIA ANN | — |
| 17775101 | SYNTHETIC ALPHA-SECRETASE AND USE THEREOF | ARMATO JR, DENNIS IGNATIUS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17912480 | ISCHEMIC HEART DISEASE ANIMAL MODEL USING 3-DIMENSIONAL BIOPRINTED OCCLUDE, AND MANUFACTURING METHOD THEREFOR | WESTON, ALYSSA G | 9d |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | WELLES, COLMAN THOMAS | 21d |
| 18065810 | NOVEL MICROORGANISM FOR POLYSTYRENE BIODEGRADATION | LEE, JAE W | 22d |
| 18395922 | NOVEL ORGANOTIN SILICATE COMPOUNDS, PREPARATION METHODS THEREOF AND PHOTORESIST COMPOSITION CONTAINING THE SAME | FRASER, STEWART A | — |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | SCHUBERG, LAURA J | — |
| 18251176 | CONSTRUCT FOR EXPRESSING MONOMERIC STREPTAVIDIN | RAYMONDA, MATTHEW HAROLD | — |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | DUFFY, PATRICIA ANN | — |
| 18030584 | NOVEL PROTEIN SPECIFICALLY BINDING TO CALRETICULIN AND HAVING HUMAN FIBRONECTIN DOMAIN III SCAFFOLD AND USE THEREOF | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1612 | 1 |
| 1684 | 1 |
| 1645 | 1 |
| 1647 | 1 |
| 1657 | 1 |
| 1656 | 1 |
| 1633 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18395922 | NOVEL ORGANOTIN SILICATE COMPOUNDS, PREPARATION METHODS THEREOF AND PHOTORESIST COMPOSITION CONTAINING THE SAME | FRASER, STEWART A | — | §102§103 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | SCHUBERG, LAURA J | 1631 | §102 | Final Rejection | — | Pending | Oct 18, 2023 |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | WELLES, COLMAN THOMAS | 1612 | §103§112 | Non-Final OA | 21d | Pending | Oct 02, 2023 |
| 18251176 | CONSTRUCT FOR EXPRESSING MONOMERIC STREPTAVIDIN | RAYMONDA, MATTHEW HAROLD | 1684 | §103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | DUFFY, PATRICIA ANN | 1645 | §103§112 | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18030584 | NOVEL PROTEIN SPECIFICALLY BINDING TO CALRETICULIN AND HAVING HUMAN FIBRONECTIN DOMAIN III SCAFFOLD AND USE THEREOF | DEBERRY, REGINA M | 1647 | §102§103DP | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18002292 | SALMONELLA STRAIN FOR TREATING CANCER AND USE THEREOF | CONSTANTINE, CHARLES Z | 1657 | §103 | Final Rejection | — | Pending | Dec 19, 2022 |
| 18065810 | NOVEL MICROORGANISM FOR POLYSTYRENE BIODEGRADATION | LEE, JAE W | 1656 | §101 | Non-Final OA | 22d | Pending | Dec 14, 2022 |
| 17912480 | ISCHEMIC HEART DISEASE ANIMAL MODEL USING 3-DIMENSIONAL BIOPRINTED OCCLUDE, AND MANUFACTURING METHOD THEREFOR | WESTON, ALYSSA G | 1633 | §102§103 | Non-Final OA | 9d | Pending | Sep 16, 2022 |
| 17775101 | SYNTHETIC ALPHA-SECRETASE AND USE THEREOF | ARMATO JR, DENNIS IGNATIUS | 1651 | §103§112 | Final Rejection | — | Pending | May 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial